Anoro Comparisons Trip Up AZ’s Bevespi In Latest COPD Study
Executive Summary
AstraZeneca has failed to show that its LAMA/LABA combo Bevespi Aerosphere is better than GSK’s Anoro Ellipta in a Phase IIIb study, a result “inconsistent” with previous data, but not surprising according to experts.
You may also be interested in...
Sun Rises For GSK's Trelegy And Shingrix While It Sets For Advair
The drug maker is in the midst of launching several new drugs, including the Shingrix vaccine, the triple COPD therapy Trelegy and the HIV regimen Juluca, hoping new drugs will drive growth as Advair sunsets.
GSK's Triple Combo COPD Drug Gets Europe Okay
Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.
AstraZeneca Respiratory Head: Tezepelumab Could Be 'Game Changer'
AstraZeneca's first in class biologic tezepelumab, which targets TSLP, has revolutionary potential in treating severe asthma, the UK drug maker's respiratory head tells Scrip.